Deucravacitinib-13C,d3 is a carbon-13 and deuterium labeled version of Deucravacitinib. Deucravacitinib (BMS-986165) is a highly efficient, selective, orally bioavailable allosteric TYK2 inhibitor with potential applications in autoimmune disease research. It selectively binds the TYK2 pseudokinase (JH2) domain (IC50=1.0 nM), blocking receptor-mediated Tyk2 activation by stabilizing the JH2 domain. Deucravacitinib inhibits the IL-12/23 and type I IFN pathways. Notably, Deucravacitinib is the first deuterated compound globally, designed de novo by the FDA, and is useful for studies in moderate to severe plaque psoriasis.